Harmony Biosciences Holdings, Inc. (HRMY) shares soared 12.7% in the last trading session to close at $29.6. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 1.8% loss over the past four weeks.The stock rallied after the company announced robust preliminary results for the third quarter of 2025. Revenues for the Wakix (pitolisant) franchise were approximately $239 million in the third quarter of 2025, reflecting an increase of 29% ...

Exhibit 99.1 HARMONY BIOSCIENCES PREANNOUNCES STRONG Q3 2025 WAKIX PERFORMANCE; RAISES 2025 REVENUE GUIDANCE To participate in the live call by phone, dial 800-274-8461 (domestic) or 203-518-9814 (international), and reference passcode HRMYQ325. The live and replay webcast of the ● WAKIX® (pitolisant) franchise delivered net revenue of approximately $239M in Q3 2025, representing 29% year-over- year revenue growth ● These results were driven by the highest ever quarterly increase in average number of patien ...

Oct 23, 2025 8:05 AM Eastern Daylight Time Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance Share PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced preliminary results for Q3 2025, highlighted by the following: "Our robust performance this quarter highlights the continued strength of WAKIX and significant market opportunity that remains ahead. I am incredibly proud of our team's focus and executional excel ...

Core Insights - The health care sector is experiencing a trend of oversold stocks, presenting potential buying opportunities for undervalued companies [1][2] Group 1: Oversold Stocks - MoonLake Immunotherapeutics (NASDAQ: MLTX) has an RSI of 21.5, with a stock price drop of approximately 86% over the past month, reaching a 52-week low of $5.95. The stock saw a 13% increase to close at $8.43 [3][7] - CorVel Corp (NASDAQ: CRVL) has an RSI of 27.2, with a stock price decline of around 14% over the past month, hitting a 52-week low of $72.15. The stock rose 0.6% to close at $73.83 [4][7] - Harmony Biosciences Holdings Inc (NASDAQ: HRMY) has an RSI of 28.9, with a stock price decrease of about 24% over the past month, reaching a 52-week low of $26.26. The stock gained 2% to close at $27.28 [4][7] Group 2: Company Updates - MoonLake Immunotherapeutics reported week-16 results from its Phase 3 VELA-1 and VELA-2 trials, using HiSCR75 as the primary endpoint [7] - CorVel's CFO Brandon T. O'Brien stepped down, impacting the company's stock performance [7] - Harmony Biosciences Holdings announced topline results from its Phase 3 RECONNECT Study for ZYN002 in Fragile X syndrome, highlighting a catalyst-rich pipeline and plans for future trials [7]

Core Insights - The health care sector is experiencing a trend of oversold stocks, presenting potential buying opportunities for undervalued companies [1][2] Group 1: Oversold Stocks - MoonLake Immunotherapeutics (NASDAQ: MLTX) has an RSI of 21.5, with a stock price drop of approximately 86% over the past month, reaching a 52-week low of $5.95. Recent price action saw a 13% increase, closing at $8.43 [3][7] - CorVel Corp (NASDAQ: CRVL) has an RSI of 27.2, with a stock price decline of around 14% over the past month, hitting a 52-week low of $72.15. The stock rose 0.6% to close at $73.83 [4][7] - Harmony Biosciences Holdings Inc (NASDAQ: HRMY) has an RSI of 28.9, with a stock price decrease of about 24% over the past month, reaching a 52-week low of $26.26. The stock gained 2% to close at $27.28 [4][7] Group 2: Company Developments - MoonLake Immunotherapeutics reported week-16 results from its Phase 3 VELA-1 and VELA-2 trials, using HiSCR75 as the primary endpoint [7] - CorVel's CFO Brandon T. O'Brien stepped down, impacting the company's stock performance [7] - Harmony Biosciences released topline results from its Phase 3 RECONNECT Study for ZYN002 in Fragile X syndrome, highlighting a catalyst-rich pipeline and plans for future trials [7]

Core Insights - Harmony Gold Mining is experiencing significant stock performance, with a Relative Strength Rating (RS Rating) moving into the 80-plus level, indicating strong market leadership [1][4] - The stock has appreciated by 600% over the past three years, reflecting robust growth and investor interest [1] - Gold prices have surged more than 46% year-to-date, contributing to the positive outlook for gold mining companies like Harmony Gold [1] Company Performance - Harmony Gold Mining is actively trying to break past its latest buy point, positioning itself as a top stock to watch in the current market [1] - The company operates gold mines in South Africa, Papua New Guinea, and Australia, diversifying its geographical presence [1] - The stock has recently achieved a Relative Strength Rating upgrade, hitting a benchmark of 90-plus, further solidifying its status among leading stocks [4] Market Trends - The current market environment shows a trend of investors seeking safe-haven assets, leading to increased interest in gold stocks [4] - Harmony Gold Mining is listed among other top stocks to buy and watch, indicating its strong performance relative to peers [4]

Core Insights - Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is identified as a promising low-priced growth stock, with analysts at H.C. Wainwright maintaining a 'Buy' rating but lowering the price target from $70 to $55, indicating a potential upside of nearly 100% [1] - The company faced a setback with its Phase 3 RECONNECT trial for ZYN002, which did not meet its primary endpoint for treating Fragile X syndrome, attributed to a higher-than-expected placebo response [2] - Despite halting the development of ZYN002 for 22q11.2 deletion syndrome, Harmony continues to demonstrate commercial strength through its product WAKIX and maintains a solid balance sheet, supporting ongoing R&D and business development efforts [3] Company Overview - Harmony Biosciences Holdings, Inc. is a Pennsylvania-based pharmaceutical company focused on therapies for rare and neurological diseases, founded in 2017 with an emphasis on empathy and innovation [4]

Core Insights - Harmony Biosciences Holdings, Inc. (HRMY) shares fell by 16.56% on September 24 following the announcement of the failure of the late-stage RECONNECT study for ZYN002 in Fragile X syndrome (FXS) [1][2] - The RECONNECT study was a randomized, double-blind, placebo-controlled trial aimed at assessing the efficacy and safety of ZYN002, a transdermal gel cannabidiol for patients aged 3 to under 30 years with FXS [1][2] - The study did not meet its primary endpoint of improving social avoidance, attributed to a higher-than-expected placebo response rate [2] Company Performance - Year-to-date, HRMY has experienced a 22.2% decline, contrasting with a 5.3% gain in the industry [3] - The company's lead drug, Wakix (pitolisant), generated revenues of $200.5 million in the second quarter [5][7] - HRMY plans to initiate phase III registrational trials for a high dose of pitolisant in narcolepsy and idiopathic hypersomnia in the fourth quarter of 2025 [5][7] Pipeline Expansion - HRMY has broadened its pipeline into rare epilepsy through the acquisition of Epygenix Therapeutics, adding EPX-100 and EPX-200 to its portfolio [6][7] - EPX-100 is currently in phase III registrational trials for Dravet Syndrome and Lennox-Gastaut Syndrome, while EPX-200 is in the pre-IND phase for developmental and epileptic encephalopathies [6]

Group 1 - U.S. stocks experienced a decline, with the Dow Jones index dropping over 150 points on Wednesday [1] - Freeport-McMoRan Inc. shares fell 16.4% to $37.94 after the company provided lower third-quarter sales guidance [1] - The company reported a tragic incident at the Grasberg Block Cave mine, resulting in two fatalities and five team members missing [1] Group 2 - Zhengye Biotechnology Holding Limited shares decreased by 28.2% to $5.02 [4] - YD Bio Ltd shares fell 15% to $17.91 [4] - Harmony Biosciences Holdings, Inc. shares dropped 14.6% to $27.36 after failing to meet primary endpoints in a clinical trial [4] - Needham reduced the price target for Harmony Biosciences from $48 to $41 [4] - Cohu, Inc. shares declined 12.7% to $19.85 following an announcement of convertible senior notes offering [4] - Rigel Pharmaceuticals, Inc. shares decreased by 12.7% to $29.69 [4] - BGM Group Ltd. shares fell 12.2% to $10.31 [4] - Worthington Enterprises, Inc. shares dipped 11.3% to $53.43 after reporting first-quarter results [4] - QMMM Holdings Limited shares decreased by 11% to $97.00 [4] - Astera Labs, Inc. shares fell 10.6% to $205.65 [4] - Sandisk Corporation shares dipped 8.2% to $97.68 [4]

Group 1: Market Overview - U.S. stocks experienced a decline, with the Dow Jones index dropping more than 150 points on Wednesday [1] Group 2: Company-Specific News - Freeport-McMoRan Inc. shares fell 16.4% to $37.94 after the company provided third-quarter sales guidance [1] - The company reported a tragic incident at the Grasberg Block Cave mine, resulting in the fatal injuries of two team members and five others remaining missing [1] - Zhengye Biotechnology Holding Limited shares decreased by 28.2% to $5.02 [4] - YD Bio Ltd shares fell 15% to $17.91 [4] - Harmony Biosciences Holdings, Inc. shares dropped 14.6% to $27.36 after its Phase 3 clinical trial for ZYN002 in Fragile X syndrome did not meet primary endpoints, leading Needham to lower its price target from $48 to $41 [4] - Cohu, Inc. shares declined 12.7% to $19.85 following the announcement of an offering of convertible senior notes [4] - Rigel Pharmaceuticals, Inc. shares fell 12.7% to $29.69 [4] - BGM Group Ltd. shares decreased by 12.2% to $10.31 [4] - Worthington Enterprises, Inc. shares dipped 11.3% to $53.43 after reporting first-quarter results [4] - QMMM Holdings Limited shares fell 11% to $97.00 [4] - Astera Labs, Inc. shares declined 10.6% to $205.65 [4] - Sandisk Corporation shares dipped 8.2% to $97.68 [4]